Loading...

Home
Stock
CYTK

CYTK News & Events

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

CYTK News

DAFNA Capital Management Reduces Stake in Biotechnology ETF

Mar 21 2026NASDAQ.COM

DAFNA Capital Management Reduces Stake in iShares Biotechnology ETF

Mar 21 2026Fool

Cytokinetics Executive's Major Stock Sale Raises Eyebrows

Mar 09 2026Fool

Cytokinetics Executive Sells Stock Options

Mar 09 2026NASDAQ.COM

MongoDB and Warner Bros Options Trading Activity

Feb 25 2026NASDAQ.COM

Cytokinetics Q4 2025 Earnings Call Highlights

Feb 25 2026seekingalpha

Cytokinetics (CYTK) Q4 2025 Earnings Transcript

Feb 25 2026NASDAQ.COM

Cytokinetics Q4 Earnings Report Analysis

Feb 24 2026seekingalpha

CYTK Events

No data

No data

CYTK Monitor News

Cytokinetics Executive's Stock Sale Raises Concerns

Cytokinetics Faces Challenges Despite FDA Approval of MYQORZO

Cytokinetics to Announce Q4 Earnings Amid FDA Approval for Aficamten

Cytokinetics stock rises amid sector rotation despite shareholder investigation

Cytokinetics Receives FDA Approval for MYQORZO, Driving Stock Surge

Cytokinetics faces shareholder investigation amid FDA review delay

CYTK Earnings Analysis

Cytokinetics Earnings Report: Key Highlights & Forecast- Intellectia AI™

Cytokinetics Q4 2024: Earnings Growth & Strategic Milestones- Intellectia AI™

People Also Watch